Details of the Drug

General Information of Drug (ID: DM6L5VO)

Drug Name

Methsuximide

Synonyms

Celontin; Mesuximid; Mesuximida; Mesuximide; Mesuximidum; Methsuximid; Metosuccimmide; Metsuccimide; Petinutin; Methsuximide [BAN]; Metosuccimmide [DCIT]; PM 396; Alpha-Methylphensuximide; Celontin (TN); Mesuximida [INN-Spanish]; Mesuximide (INN); Mesuximidum [INN-Latin]; Methsuximide (USP); Petinutin (TN); Alpha-Methyl-alpha-phenyl N-methyl succinimide; N,2-Dimethyl-2-phenylsuccinimide; N-Methyl-alpha-methyl-alpha-phenylsuccinimide; (+-)-N,2-Dimethyl-2-phenylsuccinimide; (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion; 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine; 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione; 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione; 1,3-Dimethyl-3-phenylsuccinimide; 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

Indication

Disease Entry	ICD 11	Status	REF
Epileptic seizures	8A61-8A6Z	Approved	[1], [2]

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

203.24

Topological Polar Surface Area (xlogp)

1.2

Rotatable Bond Count (rotbonds)

1

Hydrogen Bond Donor Count (hbonddonor)

0

Hydrogen Bond Acceptor Count (hbondacc)

2

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 1.4 - 2.6 hours [3]

Chemical Identifiers

Formula: C12H13NO2
IUPAC Name: 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
Canonical SMILES: CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2
InChI: InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
InChIKey: AJXPJJZHWIXJCJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 6476
ChEBI ID: CHEBI:6846
CAS Number: 77-41-8
DrugBank ID: DB05246
TTD ID: D08EOD
INTEDE ID: DR1050
ACDINA ID: D00415

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methsuximide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Methsuximide when combined with Levomilnacipran.	Chronic pain [MG30]	[24]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Methsuximide when combined with Vilazodone.	Depression [6A70-6A7Z]	[24]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Methsuximide when combined with Vortioxetine.	Depression [6A70-6A7Z]	[24]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Methsuximide when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[24]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Methsuximide and Esketamine.	Depression [6A70-6A7Z]	[25]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Methsuximide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[26]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Methsuximide and Lasmiditan.	Migraine [8A80]	[27]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methsuximide 300 mg capsule	300 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7228).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010596.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
5	The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
6	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
7	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
8	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
9	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
10	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
12	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
13	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
14	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
15	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
16	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
17	Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
18	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
19	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
20	Pfizer. Product Development Pipeline. March 31 2009.
21	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
22	Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
23	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
24	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
25	Cerner Multum, Inc. "Australian Product Information.".
26	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
27	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.